World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
101
Citations
45362
World Ranking
7869
National Ranking
4101

Maureen D. Mayes publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Maureen D. Mayes sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 381 publications — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Maureen D. Mayes D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Maureen D. Mayes sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 101 D-Index — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Maureen D. Mayes is affiliated with The University of Texas at Austin in the United States. The primary focus of their research lies within the field of Medicine, with extensive work covering specialized subfields such as Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Epidemiology, Immunology, and Dermatology. Their scholarly output reflects a significant contribution to systemic sclerosis and related diseases and other overlapping areas.

Their main topics of study include systemic sclerosis and related diseases, interstitial lung diseases and idiopathic pulmonary fibrosis, inflammatory myopathies and dermatomyositis, mast cells and histamine, dermatologic treatments and research, autoimmune bullous skin diseases, and eosinophilic disorders and syndromes. This thematic concentration aligns with their publication record across multiple respected venues.

Frequent publication venues where Mayes's work appears include:

  • Annals of the Rheumatic Diseases
  • Arthritis & Rheumatology
  • Arthritis Care & Research
  • ACR Open Rheumatology
  • Lara D. Veeken

Mayes has collaborated extensively with several researchers, reflecting sustained academic partnerships that contribute to their research output. Frequent co-authors include:

  • Shervin Assassi
  • Brett D. Thombs
  • Linda Kwakkenbos
  • Vanessa L. Malcarne
  • Leland W.K. Chung

The following recent papers exemplify the scope and focus of their contributions:

  • Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial, 2021, The Lancet Respiratory Medicine
  • Expert consensus on the management of systemic sclerosis-associated interstitial lung disease, 2023, Respiratory Research
  • Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis, 2020, Arthritis & Rheumatology
  • Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study, 2020, Journal of Psychosomatic Research
  • Machine learning predicts stem cell transplant response in severe scleroderma, 2020, Annals of the Rheumatic Diseases

Best Publications

  • 2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative

    Frank Van Den Hoogen;Dinesh Khanna;Jaap Fransen;Sindhu R. Johnson

  • Cyclophosphamide versus placebo in scleroderma lung disease.

    Donald P. Tashkin;Robert Elashoff;Philip J. Clements;Jonathan Goldin

  • Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

    Oliver Distler;Martina Gahlemann;Toby M Maher

  • Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population

    Maureen D. Mayes;James V. Lacey;Jennifer Beebe-Dimmer;Brenda W. Gillespie

  • Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis

    P Clements;P Lachenbruch;J Siebold;B White

  • Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

    Donald P. Tashkin;Michael D. Roth;Philip J. Clements;Daniel E. Furst

  • Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

    J. H. Korn;Maureen D Mayes;M. Matucci Cerinic;M. Rainisio

  • Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

    K. M. Sullivan;E. A. Goldmuntz;L. Keyes-Elstein;P. A. McSweeney

  • Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

    Donald P. Tashkin;Robert Elashoff;Philip J. Clements;Michael D. Roth

  • Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

    Marco Matucci-Cerinic;Christopher P Denton;Daniel E Furst;Maureen D Mayes

  • Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies.

    P. J. Clements;P. A. Lachenbruch;J. R. Seibold;B. Zee

  • Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis

    Dinesh Khanna;Daniel E. Furst;Philip J. Clements;Yannick Allanore

  • Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

    Christopher P. Denton;Peter A. Merkel;Daniel E. Furst;Dinesh Khanna

  • Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study

    Fredrick M. Wigley;Robert A. Wise;James R. Seibold;Deborah A. McCloskey

  • Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis

    L. Van Bon;L. Van Bon;A. J. Affandi;A. J. Affandi;J. Broen;J. Broen;R. B. Christmann

  • Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus

    Timothy R.D.J. Radstake;Olga Y Gorlova;Blanca Rueda;Jose Ezequiel Martin

  • High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial

    Philip J. Clements;Daniel E. Furst;Weng Kee Wong;Maureen Mayes

  • Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon

    Peter A. Merkel;Peter A. Merkel;Karen Herlyn;Richard W. Martin;Jennifer J. Anderson

  • Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.

    James R. Seibold;Joseph H. Korn;Robert Simms;Phillip J. Clements

  • Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High‐dose versus low‐dose penicillamine trial

    Philip J. Clements;Eric L. Hurwitz;Weng Kee Wong;James R. Seibold

Frequent Co-Authors

Daniel E. Furst
Daniel E. Furst University of California, Los Angeles
Dinesh Khanna
Dinesh Khanna University of Michigan–Ann Arbor
Frank C. Arnett
Frank C. Arnett The University of Texas Health Science Center at Houston
Virginia D. Steen
Virginia D. Steen Georgetown University
John D. Reveille
John D. Reveille The University of Texas Health Science Center at Houston
John Varga
John Varga University of Michigan–Ann Arbor
Christopher P. Denton
Christopher P. Denton University College London
Philip J. Clements
Philip J. Clements University of California, Los Angeles
Fredrick M. Wigley
Fredrick M. Wigley Johns Hopkins University
Filemon K. Tan
Filemon K. Tan The University of Texas Health Science Center at Houston

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA offers diverse pathways beyond the traditional MD. Many students and working professionals now pursue flexible online degrees to advance their healthcare expertise or shift career tracks.

For those interested in healthcare leadership, the top cahme accredited mha programs provide rigorous training in health administration, fully online, and with respected accreditation. Nurses seeking to upgrade qualifications without pausing their careers can enroll in online rn-bsn programs without clinicals. These programs eliminate clinical requirements for experienced RNs—saving time while boosting credentials.

For advanced practice, Doctor of Nursing Practice degrees are increasingly popular. Options such as the shortest dnp program online allow professionals to achieve the terminal degree in nursing efficiently. Those seeking a manageable workload can explore the easiest dnp programs, designed with flexibility for busy practitioners.

These alternative online degrees open doors for healthcare professionals to climb the career ladder or seamlessly enter new specialties, all while balancing work and life commitments.

Best Scientists Citing Maureen D. Mayes

Trending Scientists

Recently Published Articles